Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

Bridgette J. Picou, LVN, ACLPN, presented research on the lived experiences of women living with HIV and going through ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

The Kingdom of Eswatini has the highest HIV/AIDS incidence in the world. However, the mission of the Piggs Peak Partnership ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

HIV conference opened in San Francisco Sunday, March 9, under a cloud of uncertainty in the face of the Trump ...

An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...